Navigation Links
Global Healthcare Leader Deploys QUOSA's Literature Management Tools
Date:10/22/2013

PHILADELPHIA, October 22, 2013 /PRNewswire/ --

Sanofi will use QUOSA, part of Elsevier Life Science Solutions for drug discovery and development, to support adverse event monitoring

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralized repository of product-related scientific literature. This centralized repository supports Sanofi's Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates.

"Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever-growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety," said Michael Rai, General Manager of QUOSA at Elsevier. "In response to our many conversations with Information Professionals, we have finely tuned QUOSA to complement current processes to provide a stable, efficient and scalable solution which continues to evolve with future needs. We look forward to working with Sanofi to manage this flow of information and support its Pharmacovigilance teams' work."

QUOSA provides software and services to life science companies, enabling them to centralize repositories of scientific literature related to drugs and medical devices, as well as receive alerts about new articles related to their products and other market developments. These not only help Pharmacovigilance and Medical Affairs teams carry out their work effectively and quickly, they also ensure sound information management processes and compliance with regulatory requirements.

QUOSA's pharmacovigilance solution features three elements that help companies meet their literature tracking objectives. First, Elsevier provides prompt customized professional services through its dedicated Life Sciences Integration Services team. Second, QUOSA can be used as either a desktop application or browser-based technology, facilitating secure and scalable information sharing across multiple regions. Third, QUOSA easily integrates with already existing literature resources like third-party publisher platforms, A&I databases like Embase, and document delivery vendors.

QUOSA is part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including TargetInsights®, Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, PharmaPendium® and Embase®.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Liz Griffioen
Elsevier
+31-20-485-2247
L.Griffioen@elsevier.com



'/>"/>
SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Animal/Veterinary Vaccines Market - 2013 Report
2. mHealth Apps & Solutions Market - Global Trends & Forecast to 2018
3. Anti-Adhesion Products - Global Strategic Business Report
4. Global Cardiac Resynchronization Therapy (CRT) Devices - Market Growth Analysis, 2009-2015
5. Global Strategic Business Radiopharmaceuticals Report 2013-2018: High Costs of Drug Development Piques Manufacturers
6. Electrophysiology Devices Market is Expected to Reach USD 5.5 Billion Globally in 2019: Transparency Market Research
7. Hyland Software Partners with the Global Center for Healthcare Innovation in Cleveland
8. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
9. UBM Canon, the Global Authority on the MedTech Industry, Announces the Launch of MedTech World
10. Dental Restorative Supplies - Global Strategic Business Report - 2013-2018
11. Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
(Date:12/8/2016)... 8, 2016 According to the research ... Market is expected to be worth US$9.7 bn by ... 2015. Between the forecast years of 2016 and 2024, the ... 7.9%. The leading players operating in the global diabetes injection ... AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research ...
(Date:12/8/2016)... According to a new market research report "Wearable Medical Devices Market ... Use (Sports, Fitness, RPM), Type (Smart watch, Patch), Distribution Channel (Pharmacy, Hypermarket) ... of value, is projected to reach 12.14 Billion by 2021 from USD ... period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
Breaking Medicine News(10 mins):